ONCY Oncolytics Biotech Inc. - Common Shares
$0.79
Price · May 20, 2026
Fundamentals as of May 14, 2026
52W Range
$0–$2
39% of range
Analyst Rating
BUY
8 analysts
Price Target
$5
+545% upside
P/E (TTM)
-2.9
ROE
11480.6%
Net Profit Margin
—
ONCY Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$0.79
Market Cap
$94M
P/E (TTM)
-2.9
EPS (TTM)
$-0.30
Revenue (TTM)
—
Div Yield
—
ROE
11480.6%
Debt/Equity
—
52W Range
$0 – $2
ONCY Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
$-0.30
2024-12-31
→
2025-12-31
Free Cash Flow
$-20M
2025-12-31
→
2025-12-31
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
ONCY
Peer Median
P/E (TTM)
-2.9
—
P/B
-24.7
3.5
Price / FCF
-4.7
—
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
ONCY
Peer Median
ROA
-273.9%
-40.8%
ROE
11480.6%
-46.2%
ROIC
758.2%
—
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
ONCY
Peer Median
Current Ratio
1.1
6.9
Quick Ratio
0.9
—
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
ONCY
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
ONCY
Peer Median
ONCY Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
8 analysts
- Strong Buy 1 12.5%
- Buy 5 62.5%
- Hold 2 25.0%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
6 analysts · 2026-05-19
Median
$4.25
Mean
$5.07
← Below all targets
$0.79
Low
$2.94
High
$9.89
Median target
$4.25
+440.2%
Mean target
$5.07
+544.7%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
0.01%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| Sept. 30, 2025 | $-0.14 | $-0.10 | -0.04% |
| June 30, 2025 | $-0.07 | $-0.11 | 0.04% |
| March 31, 2025 | $-0.08 | $-0.10 | 0.02% |
| Dec. 31, 2024 | $-0.10 | $-0.12 | 0.02% |
Peer Comparison Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| ONCY | $94M | -2.9 | — | — | 11480.6% | — |
| ZYME | $1.97B | -24.4 | 38.9% | -76.6% | -26.9% | — |
| ACOG | $141M | -5.5 | — | -202.2% | -43.8% | — |
| ENGN | — | — | — | — | — | — |
| EDSA | $18M | — | — | — | -51.3% | — |
| XENE | $3.59B | -10.3 | — | -4612.1% | -56.9% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 14
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| R&D Expense | $13M | $15M | |
| SG&A Expense | $15M | $10M | |
| Operating Expenses | $29M | $26M | |
| Operating Income | $-29M | $-26M | |
| Interest Income | $386.0K | $975.0K | |
| Other Non-op | $45.0K | $3M | |
| Pretax Income | $-29M | $-23M | |
| Income Tax | $79.0K | $95.0K | |
| Net Income | $-29M | $-23M | |
| EPS (Basic) | $-0.30 | $-0.30 | |
| EPS (Diluted) | $-0.30 | $-0.30 | |
| Shares (Basic) | 95,857,147 | 76,482,914 | |
| Shares (Diluted) | 95,857,147 | 76,482,914 | |
| EBITDA | $-29M | · |
Balance Sheet 19
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $5M | $11M | |
| Prepaid Expense | $1M | $1M | |
| Current Assets | $7M | $12M | |
| PP&E (Net) | $228.0K | $286.0K | |
| PP&E (Gross) | $754.0K | $725.0K | |
| Accum. Depreciation | $526.0K | $439.0K | |
| Total Assets | $8M | $13M | |
| Accounts Payable | $4M | $756.0K | |
| Accrued Liabilities | $2M | $3M | |
| Current Liabilities | $6M | $5M | |
| Capital Leases | $370.0K | $561.0K | |
| Total Liabilities | $11M | $10M | |
| Common Stock | $0 | $0 | |
| Paid-in Capital | $419M | $398M | |
| Retained Earnings | $-429M | $-401M | |
| AOCI | $6M | $6M | |
| Stockholders' Equity | $-4M | $3M | |
| Liabilities + Equity | $8M | $13M | |
| Shares Outstanding | 108,021,271 | 80,020,131 |
Cash Flow 9
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Stock-based Comp | $3M | $2M | |
| Deferred Tax | $0 | $0 | |
| Operating Cash Flow | $-20M | $-20M | |
| CapEx | $6.0K | $174.0K | |
| Investing Cash Flow | $-6.0K | $-174.0K | |
| Financing Cash Flow | $14M | $5M | |
| Net Change in Cash | $-6M | $-15M | |
| Taxes Paid | $67.0K | $134.0K | |
| Free Cash Flow | $-20M | · |
Profitability 3
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| ROA | -273.9% | · | |
| ROE | 11480.6% | · | |
| ROIC | 758.2% | · |
Liquidity & Solvency 2
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Current Ratio | 1.1 | · | |
| Quick Ratio | 0.9 | · |
Valuation (TTM) 7
| Metric | Trend | 2025 | 2024 |
|---|---|---|---|
| Net Income TTM | $-29M | · | |
| Market Cap | $94M | · | |
| P/E | -2.9 | · | |
| P/B | -24.7 | · | |
| P / Cash Flow | -4.7 | · | |
| P / FCF | -4.7 | · | |
| Earnings Yield | -34.5% | · |
Income Statement 12
| Metric | Trend | Q1 2026 | Q4 2025 |
|---|---|---|---|
| R&D Expense | $5M | · | |
| SG&A Expense | $5M | · | |
| Operating Expenses | $9M | · | |
| Operating Income | $-9M | · | |
| Interest Income | $44.0K | · | |
| Other Non-op | $38.0K | · | |
| Net Income | $-9M | · | |
| EPS (Basic) | $-0.08 | · | |
| EPS (Diluted) | $-0.08 | · | |
| Shares (Basic) | 112,292,579 | · | |
| Shares (Diluted) | 112,292,579 | · | |
| EBITDA | $-9M | · |
Balance Sheet 19
| Metric | Trend | Q1 2026 | Q4 2025 |
|---|---|---|---|
| Cash & Equivalents | $5M | $5M | |
| Prepaid Expense | $1M | $1M | |
| Current Assets | $7M | $7M | |
| PP&E (Net) | $218.0K | $228.0K | |
| PP&E (Gross) | · | $754.0K | |
| Accum. Depreciation | · | $526.0K | |
| Total Assets | $8M | $8M | |
| Accounts Payable | $3M | $4M | |
| Accrued Liabilities | $3M | $2M | |
| Current Liabilities | $5M | $6M | |
| Capital Leases | $342.0K | $370.0K | |
| Total Liabilities | $13M | $11M | |
| Common Stock | $0 | $0 | |
| Paid-in Capital | $427M | $419M | |
| Retained Earnings | $-439M | $-429M | |
| AOCI | $6M | $6M | |
| Stockholders' Equity | $-5M | $-4M | |
| Liabilities + Equity | $8M | $8M | |
| Shares Outstanding | 116,128,162 | 108,021,271 |
Cash Flow 9
| Metric | Trend | Q1 2026 | Q4 2025 |
|---|---|---|---|
| Stock-based Comp | $2M | · | |
| Operating Cash Flow | $-7M | · | |
| CapEx | $6.0K | · | |
| Investing Cash Flow | $-6.0K | · | |
| Stock Issued | $8M | · | |
| Net Stock Activity | $8M | · | |
| Financing Cash Flow | $8M | · | |
| Net Change in Cash | $291.0K | · | |
| Free Cash Flow | $-7M | · |
Profitability 2
| Metric | Trend | Q1 2026 | Q4 2025 |
|---|---|---|---|
| ROA | -226.5% | · | |
| ROE | 360.3% | · |
Liquidity & Solvency 2
| Metric | Trend | Q1 2026 | Q4 2025 |
|---|---|---|---|
| Current Ratio | 1.4 | · | |
| Quick Ratio | 1.0 | · |
Valuation (TTM) 4
| Metric | Trend | Q1 2026 | Q4 2025 |
|---|---|---|---|
| Market Cap | $99M | · | |
| P/B | -19.2 | · | |
| P / Cash Flow | -13.5 | · | |
| P / FCF | -13.5 | · |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Income Statement
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| Net Income | $-29M | $-23M |
| Diluted EPS | $-0.30 | $-0.30 |
Balance Sheet
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| Current Ratio | 1.1 | — |
| Quick Ratio | 0.9 | — |
Cash Flow
| 2025-12-31 | 2024-12-31 | |
|---|---|---|
| Free Cash Flow | $-20M | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.